BACKGROUND: The natural outcome of infection with hepatitis C virus (HCV) varies substantially among individuals. However, little is known about host and viral factors associated with a self-limiting or chronic evolution of HCV infection. METHODS: From 1 January 2001 through 31 December 2008, a consecutive series of 65 patients from Rio de Janeiro, Brazil, with a well-documented diagnosis of acute HCV infection, acquired via various routes, were enrolled in this study. Patients were prospectively followed up for a median of 40 months after the estimated date of HCV infection with serial measurements of serum alanine aminotransferase, HCV RNA, and anti-HCV antibodies. Spontaneous viral clearance (SVC) was defined as undetectable levels of HCV RNA in serum, in the absence of treatment, for 3 consecutive HCV polymerase chain reaction tests within the first 6 months of follow-up. Cox proportional hazards regression was used to identify host and viral predictors of SVC. RESULTS: The cumulative rate of SVC was 44.6% (95% confidence interval, 32.3%-57.5%). Compared with chronic HCV evolution, patients with self-limiting disease had significantly lower peak levels of anti-HCV antibodies (median, 109.0 vs 86.7 optical density-to-cutoff ratio [od/co]; P<.02), experienced disease symptoms more frequently (69.4% vs 100%; P<.001), and had lower viral load at first clinical presentation (median, 4.3 vs 0.0 log copies; P=.01). In multivariate analyses, low peak anti-HCV level (<93.5 od/co) was the only independent predictor for SVC; the hazard ratio compared with high anti-HCV levels (> or =93.5 od/co) was 2.62 (95% confidence interval, 1.11-6.19; P=.03). CONCLUSION: Our data suggest that low levels of anti-HCV antibodies during the acute phase of HCV infection are independently related to spontaneous viral clearance.
BACKGROUND: The natural outcome of infection with hepatitis C virus (HCV) varies substantially among individuals. However, little is known about host and viral factors associated with a self-limiting or chronic evolution of HCV infection. METHODS: From 1 January 2001 through 31 December 2008, a consecutive series of 65 patients from Rio de Janeiro, Brazil, with a well-documented diagnosis of acute HCV infection, acquired via various routes, were enrolled in this study. Patients were prospectively followed up for a median of 40 months after the estimated date of HCV infection with serial measurements of serum alanine aminotransferase, HCV RNA, and anti-HCV antibodies. Spontaneous viral clearance (SVC) was defined as undetectable levels of HCV RNA in serum, in the absence of treatment, for 3 consecutive HCV polymerase chain reaction tests within the first 6 months of follow-up. Cox proportional hazards regression was used to identify host and viral predictors of SVC. RESULTS: The cumulative rate of SVC was 44.6% (95% confidence interval, 32.3%-57.5%). Compared with chronic HCV evolution, patients with self-limiting disease had significantly lower peak levels of anti-HCV antibodies (median, 109.0 vs 86.7 optical density-to-cutoff ratio [od/co]; P<.02), experienced disease symptoms more frequently (69.4% vs 100%; P<.001), and had lower viral load at first clinical presentation (median, 4.3 vs 0.0 log copies; P=.01). In multivariate analyses, low peak anti-HCV level (<93.5 od/co) was the only independent predictor for SVC; the hazard ratio compared with high anti-HCV levels (> or =93.5 od/co) was 2.62 (95% confidence interval, 1.11-6.19; P=.03). CONCLUSION: Our data suggest that low levels of anti-HCV antibodies during the acute phase of HCV infection are independently related to spontaneous viral clearance.
Authors: T Santantonio; E Sinisi; A Guastadisegni; C Casalino; M Mazzola; A Gentile; G Leandro; G Pastore Journal: Dig Liver Dis Date: 2003-02 Impact factor: 4.088
Authors: Kathleen E Corey; Andrew S Ross; Alysse Wurcel; Julian Schulze Zur Wiesch; Arthur Y Kim; Georg M Lauer; Raymond T Chung Journal: Clin Gastroenterol Hepatol Date: 2006-08-22 Impact factor: 11.382
Authors: A Takaki; M Wiese; G Maertens; E Depla; U Seifert; A Liebetrau; J L Miller; M P Manns; B Rehermann Journal: Nat Med Date: 2000-05 Impact factor: 53.440
Authors: F Komurian-Pradel; G Paranhos-Baccalà; M Sodoyer; P Chevallier; B Mandrand; V Lotteau; P André Journal: J Virol Methods Date: 2001-06 Impact factor: 2.014
Authors: L I Nikolaeva; N P Blokhina; N N Tsurikova; N V Voronkova; M I Miminoshvili; D M Braginsky; O N Yastrebova; O B Booynitskaya; O V Isaeva; M I Michailov; A I Archakov Journal: J Viral Hepat Date: 2002-11 Impact factor: 3.728
Authors: J Tilman Gerlach; Helmut M Diepolder; Reinhart Zachoval; Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Winfried W Schraut; C Albrecht Schirren; M Waechtler; M Backmund; Gerd R Pape Journal: Gastroenterology Date: 2003-07 Impact factor: 22.682
Authors: Harald Hofer; Thomas Watkins-Riedel; Oskar Janata; Edward Penner; Heidemarie Holzmann; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci Journal: Hepatology Date: 2003-01 Impact factor: 17.425
Authors: C Mazzeo; F Azzaroli; S Giovanelli; A Dormi; D Festi; A Colecchia; A Miracolo; P Natale; G Nigro; A Alberti; E Roda; G Mazzella Journal: Gut Date: 2003-07 Impact factor: 23.059
Authors: Alexander M Strasak; Arthur Y Kim; Georg M Lauer; Paulo S de Sousa; Cleber F Ginuino; Carlos A Fernandes; Carlos E Velloso; Adilson J de Almeida; Jaqueline M de Oliveira; Clara F Yoshida; Julian Schulze zur Wiesch; Gláucia Paranhos-Baccalá; Stefan Lang; Larry J Brant; Hanno Ulmer; Susanne Strohmaier; Lalit Kaltenbach; Elisabeth Lampe; Lia L Lewis-Ximenez Journal: BMC Infect Dis Date: 2011-01-12 Impact factor: 3.090
Authors: Ayman El Garf; Bassel El Zorkany; Rasha Gheith; Hala Sheba; Geilan Abdel Moneim; Kamal El Garf Journal: Rheumatol Int Date: 2011-07-27 Impact factor: 2.631
Authors: Enea Spada; Pietro Amoroso; Gloria Taliani; Ornella Zuccaro; Piergiorgio Chiriacò; Patrizia Maio; Giuseppe Maio; Maria Luisa Esposito; Corrado Mariano; Roberto Rinaldi; Pietro Bellissima; Maria Elena Tosti; Paola Del Porto; Ruggiero Francavilla; Vincenzo Mellace; Anna Rosa Garbuglia; Antonella Folgori; Alfonso Mele Journal: Clin Infect Dis Date: 2013-06-19 Impact factor: 9.079